- Home
- WERN vs MNKD Comparison
WERN vs MNKD Comparison
Compare WERN & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WERN
- MNKD
- Stock Information
- Founded
- WERN 1956
- MNKD 1991
- Country
- WERN United States
- MNKD United States
- Employees
- WERN N/A
- MNKD N/A
- Industry
- WERN Trucking Freight/Courier Services
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- WERN Industrials
- MNKD Health Care
- Exchange
- WERN Nasdaq
- MNKD Nasdaq
- Market Cap
- WERN 1.7B
- MNKD 1.4B
- IPO Year
- WERN N/A
- MNKD 2004
- Fundamental
- Price
- WERN $29.07
- MNKD $3.60
- Analyst Decision
- WERN Hold
- MNKD Buy
- Analyst Count
- WERN 14
- MNKD 4
- Target Price
- WERN $30.86
- MNKD $9.75
- AVG Volume (30 Days)
- WERN 898.5K
- MNKD 3.5M
- Earning Date
- WERN 07-29-2025
- MNKD 08-06-2025
- Dividend Yield
- WERN 1.93%
- MNKD N/A
- EPS Growth
- WERN N/A
- MNKD 228.27
- EPS
- WERN 0.29
- MNKD 0.10
- Revenue
- WERN $2,973,292,000.00
- MNKD $297,595,000.00
- Revenue This Year
- WERN $0.55
- MNKD $13.72
- Revenue Next Year
- WERN $6.33
- MNKD $15.21
- P/E Ratio
- WERN $101.21
- MNKD $34.71
- Revenue Growth
- WERN N/A
- MNKD 32.50
- 52 Week Low
- WERN $23.02
- MNKD $3.52
- 52 Week High
- WERN $42.48
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- WERN 63.15
- MNKD 34.29
- Support Level
- WERN $26.92
- MNKD $3.52
- Resistance Level
- WERN $27.86
- MNKD $4.00
- Average True Range (ATR)
- WERN 0.89
- MNKD 0.16
- MACD
- WERN 0.17
- MNKD -0.00
- Stochastic Oscillator
- WERN 83.83
- MNKD 16.67
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.